NCT03967275 (SYMBOLpreclini) is a clinical trial of bone marrow harvest in Bone Marrow Donor, sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

Who is sponsoring NCT03967275?

NCT03967275 is sponsored by Fondation Ophtalmologique Adolphe de Rothschild.

What drugs are being tested in NCT03967275?

Interventions in NCT03967275: bone marrow harvest.

What condition does NCT03967275 study?

NCT03967275 studies Bone Marrow Donor.

Is NCT03967275 still recruiting?

NCT03967275 is currently completed. Last updated 5 July 2022.

Last reviewed 2022-07-05 · How we verify

NCT03967275: SYMBOLpreclini

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subconjunctival Injection of Allogeneic Mesenchymal Stem Cells in Severe Ocular Chemical Burn

Completed Last updated 5 July 2022

What this trial tests

trial testing bone marrow harvest in Bone Marrow Donor in 7 participants. Completed in 1 June 2022.

Timeline

9 September 2020

Primary endpoint
1 June 2022

1 June 2022

Quick facts

Lead sponsor	Fondation Ophtalmologique Adolphe de Rothschild
Status	Completed
Study type	OBSERVATIONAL
Enrollment	7
Start date	9 September 2020
Primary completion	1 June 2022
Estimated completion	1 June 2022
Sites	1 location across France

Drugs / interventions tested

bone marrow harvest

Conditions studied

Bone Marrow Donor — all drugs for Bone Marrow Donor →

Sponsor

Fondation Ophtalmologique Adolphe de Rothschild — full company profile →

Who can join

18 and older, any sex, with Bone Marrow Donor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this pre-clinical study is to demonstrate the robustness of Bone Marrow derived Mesenchymal Stem Cells (BM-MSC) production, to treat patients with severe eye burns. For bone marrow donors who agree to participate, a 10 ml BM sample will be collected apart the 1 liter BM dedicated to transplantation. A maximum of three donors of allogeneic BM-MSCs will be included. A ready-to-use BM-MSC suspension will be produced and stored for 10 years to accumulate data about stability of cryopreserved cells.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Subconjunctival injection of mesenchymal stem cells for corneal failure due to limbal stem cell deficiency: state of the art.
Galindo S, de la Mata A, López-Paniagua M, Herreras JM, et al · · 2021 · cited 51× · PMID 33441175 · DOI 10.1186/s13287-020-02129-0
Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos.
Alonso-Alonso ML, García-Posadas L, Diebold Y. · · 2022 · cited 35× · PMID 33904115 · DOI 10.1007/s12015-021-10155-5
Applications of mesenchymal stem cells in ocular surface diseases: sources and routes of delivery.
Soleimani M, Masoumi A, Momenaei B, Cheraqpour K, et al · · 2023 · cited 27× · PMID 36719365 · DOI 10.1080/14712598.2023.2175605
Goals and Challenges of Stem Cell-Based Therapy for Corneal Blindness Due to Limbal Deficiency.
Calonge M, Nieto-Miguel T, de la Mata A, Galindo S, et al · · 2021 · cited 24× · PMID 34575560 · DOI 10.3390/pharmaceutics13091483
The Myofibroblast Fate of Therapeutic Mesenchymal Stromal Cells: Regeneration, Repair, or Despair?
Younesi FS, Hinz B. · · 2024 · cited 7× · PMID 39201399 · DOI 10.3390/ijms25168712
Derivation of Limbal Stem Cells from Human Adult Mesenchymal Stem Cells for the Treatment of Limbal Stem Cell Deficiency.
Cadenas-Martin M, Arnalich-Montiel F, Miguel MP. · · 2023 · cited 4× · PMID 36768672 · DOI 10.3390/ijms24032350

Verify or expand the search:

Other Fondation Ophtalmologique Adolphe de Rothschild trials

Trials by the same sponsor.

NCT04701619 — Immuno-inflammatory Profile and Response to Ischemic Stroke Reperfusion Therapies (IMMUNOSTROKE) · NA · not yet recruiting
NCT04763161 — Immuno-inflammation in the Acute Phase of an Ischaemic Cerebral Accident Managed by Decompressive Hemicraniectomy: a Cas · not yet recruiting
NCT06264531 — Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous M · Phase 2, PHASE3 · recruiting
NCT06895044 — Evolution of Ocular Growth in Myopic Children: A Prospective Cohort Study · recruiting
NCT06644196 — Creation of a Database of Images of the Eye With the Holographic Doppler Laser · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03967275 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fondation Ophtalmologique Adolphe de Rothschild
Last refreshed: 5 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03967275.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing